Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Headline outcomes only

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

Tacrolimus showed no clear difference in total adverse events compared with beclometasone (low certainty).

1 finding from 1 review

Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

Tacrolimus showed no clear difference in total adverse events compared with placebo (low certainty).

1 finding from 1 review

Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found